In8Bio, Inc. - INAB STOCK NEWS

IN8bio (NASDAQ: INAB) has unveiled promising preclinical data from its gamma-delta (γδ) T cell engager (TCE) platform at AACR 2025. The company's novel platform demonstrates significant γδ T cell expansion and activation without serious side effects like cytokine release syndrome.

The platform's lead molecules, INB-619 (targeting CD19) and INB-633 (targeting CD33), showed potent anti-cancer activity in leukemia models at low picomolar concentrations. Unlike traditional TCEs that activate all T cells through CD3, IN8bio's platform specifically activates γδ T cells, potentially offering a safer alternative with minimal inflammatory cytokine release.

Key findings show both molecules successfully expanded Vδ1+ and Vδ2+ cell subsets and demonstrated strong cancer-killing capabilities without triggering dangerous cytokine responses. The platform's off-the-shelf nature, requiring no genetic engineering, suggests potential for scalable immunotherapy development for both cancer and autoimmune diseases.

IN8bio (NASDAQ: INAB) has announced it will present new preclinical data on its novel gamma-delta (γδ) T cell engager platform at the AACR Annual Meeting 2025 in Chicago. The presentation will showcase the company's innovative approach to cancer immunotherapy, combining gamma-delta T cells' innate tumor-recognition capabilities with bispecific engagers.

The research focuses on overcoming limitations of current CD-3 based engager therapies by leveraging unique properties of gamma-delta T cells, including tissue residence, phagocytosis, and low IL-6 secretion. Early findings in AML and B-ALL demonstrate potential for targeted immune responses against multiple antigens.

The poster presentation titled 'A novel gamma-delta T cell engager platform for cancer immunotherapy' (Abstract #7321) will be presented on Wednesday, April 30, 2025, from 9:00 AM to 12:00 PM CT.

IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies, has announced its participation in the 11th Annual Immuno-Oncology 360° Conference 2025 in Boston, MA from March 24-26, 2025.

William Ho, CEO and co-founder, will serve as Co-Chair for Day 2 on March 25, leading key sessions including:

• Welcome remarks and discussion on 'Tackling the Tough Questions in IO for Autoimmunity Disease' at 8:15 AM EDT
• Chairing the 'State of the IO Market, Investments and Deals Plenary'
• Presentation on 'Picking our Horse in the Race for Autoimmunity: The Gamma-Delta T cell Engager' at 4:35 PM EDT

The presentations will highlight IN8bio's recently announced INB-619 T cell engager program for oncology and autoimmune diseases, focusing on the potential of gamma-delta T cell engagers in addressing autoimmunity.

IN8bio (INAB) reported its Q4 and full-year 2024 financial results, highlighting significant clinical progress in its gamma-delta T cell therapies. The company's INB-100 program demonstrated 100% long-term durable response rates in high-risk AML patients as of January 2025. The Phase 1 INB-200 trial for glioblastoma showed promising durability, with five patients remaining alive and one patient progression-free for 40.5 months.

Financial highlights include R&D expenses of $17.2M for 2024 (vs $16.8M in 2023), G&A expenses of $12.6M (vs $13.5M), and a net loss of $30.7M ($0.57 per share). The company ended 2024 with cash of $11.1M, raised additional $4.1M in February 2025, and expects runway into March 2026.

IN8bio introduced its INB-600 platform featuring a novel gamma-delta T Cell engager targeting CD19 for oncology and autoimmune diseases. The company implemented cost-saving measures and paused the Phase 2 INB-400 glioblastoma program to optimize resource allocation.

IN8bio (NASDAQ: INAB) has unveiled INB-600, a novel gamma-delta (γδ) T cell-based TCE platform designed to overcome the limitations of current γδ TCEs. The platform's first candidate, INB-619, targets CD19 for applications in leukemias, lymphomas, and autoimmune diseases.

Key preclinical findings for INB-619 include:

• Rapid B-cell depletion with γδ T cells expanding up to 450-fold
• Simultaneous activation of both Vδ1+ and Vδ2+ T cell subsets
• Lower IL-6 secretion, potentially reducing risks of cytokine release syndrome (CRS) and neurotoxicity (ICANs)

The platform represents the first known approach capable of sustained γδ T cell expansion, offering potentially greater safety and tolerability compared to current CAR-T and TCE approaches. IN8bio plans to evaluate INB-619 in preclinical studies and seek partners for future IND-enabling trials.

IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. William Ho, CEO and co-founder, will deliver a presentation on Monday, March 3, 2025, at 10:30 a.m. ET.

Interested parties can access both the live webcast and replay of the presentation through the 'Events and Presentations' section within the News & Presentations area on IN8bio's investor relations website at https://investors.in8bio.com.

IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has announced its participation in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. The company's CEO and co-founder, William Ho, will deliver a presentation on Tuesday, February 25, 2025, at 11:00 a.m. ET.

The presentation will be accessible through a live webcast, with a replay option available afterward. Interested parties can access the webcast through the provided link or find it in the 'Events and Presentations' section under News & Presentations on IN8bio's investor relations website.

IN8bio (Nasdaq: INAB) presented Phase 1 data for INB-100, its allogeneic gamma-delta T cell therapy, showing significant promise in treating high-risk acute myeloid leukemia (AML). The data revealed zero relapses in AML patients with a median follow-up of 20.1 months. The therapy demonstrated impressive outcomes with a 90.9% progression-free survival rate and 100% overall survival at one year.

The treatment showed a favorable safety profile with no cytokine release syndrome, neurotoxicity, or dose-limiting toxicities. Evidence of in vivo expansion and long-term persistence of gamma-delta T cells was observed. With approximately 20,000 new AML cases and 11,500 deaths annually in the U.S., and post-HSCT relapse occurring in up to 50% of patients, INB-100 addresses a significant unmet medical need.

The company plans to complete enrollment of the expansion cohort in 2025, with FDA confirming relapse-free survival as an acceptable primary endpoint for a future pivotal trial.

IN8bio (NASDAQ: INAB) reported updated results from its Phase 1 trial of INB-100, an allogeneic gamma-delta T cell therapy for acute myeloid leukemia (AML) patients. 100% of AML patients remain in complete remission with a median follow-up of 20.1 months, with the original cohort reaching a median CR of 23.3 months. Several patients have maintained remission for over three years.

The trial demonstrated significantly higher survival rates compared to historical data, with 90.9% progression-free survival (PFS) and 100% overall survival (OS) at one year across all patients. For AML patients specifically, both PFS and OS were 100% at one year. The therapy shows particular promise in older, high-risk patients receiving reduced intensity conditioning, with a median age of 68. Notably, the treatment has been well-tolerated with no cytokine release syndrome or neurotoxicity, and manageable graft-versus-host disease.